Aspect Biosystems Raises US $115M Series B: Advancing the Future of Regenerative Medicine

As early investors in breakthrough hard tech companies, we are constantly seeking innovators who push the boundaries of what's possible in human and planetary health. Today, we're excited to announce  Aspect Biosystems has secured US$115 million Series B financing led by Dimension to advance their groundbreaking work in bioprinted tissue therapeutics. 

From our earliest interactions with Aspect Biosystems, we recognized their unique potential to transform regenerative medicine. Their innovative approach combines AI-powered bioprinting technology with advanced biomaterials to develop disease-modifying treatments for complex metabolic and endocrine disorders. This latest funding round, will accelerate the development of their therapeutic pipeline and expand their full-stack tissue therapeutic platform. 

We've always believed that the most impactful innovations often emerge at the intersection of multiple technologies. Aspect exemplifies this principle, bringing together advanced materials, AI, and biotechnology to pioneer a new category of regenerative medicine. As they enter this next phase of growth, we're more confident than ever in their ability to deliver on their mission of developing functional cures for serious diseases.